Studies exploring pathological predictors of response to neoadjuvant chemotherapy have found high Ki67 and PDL1 expression and abundance of tumor-infiltrating lymphocytes to predict pathological complete response (pCR) [6, 7]. This evidence concerns the gene MKI67 and neoplasm.